Recent research shows that mutated BRAF is presented in the majority of LCH cases and increases the risk of recurrence, suggesting that vemurafenib, which is an inhibitor of the B-Raf enzyme, can be used to treat LCH (1, 43, 44). Here, BRAF is linked to Langerhans cell histiocytosis.